We tackled this challenge using a novel NLP-based approach and created a "Trend Landscape Map". The map is designed to be a comprehensive resource and provides information about emerging concepts in the field of immuno-oncology across various levels -right from a panoramic bird's eye view down to zoomed in views of specific concepts. The intrinsic value of the map has been enhanced by incorporating information about growth and size of the field giving a nuanced view. The four major areas where most of the identified emerging concepts were clustered are: types of targets, therapies, biomarkers, and cancers. Areas where relative growth is considerably higher than the absolute number of publications represent potential lacunae of interest. For example, while immune checkpoint molecules, PD-1 and PD-L1, continue to show steady growth and is supported by the existence of several PD-1 targeted US FDA approved therapeutics, other immune checkpoint molecules such as TIGIT, B7-H3, A2AR, and LAG3 show high relative growths with low absolute number of publications. A few other key areas of emergence worth highlighting are CAR therapy especially CAR-NK and CD19 CAR-T; cancer vaccines especially RNA-based and nanovaccines; lipid-based and membrane-coated nanoparticles as modes of delivery systems. Biomarkers and therapeutic targets in immunooncology are closely tied and show a large degree of overlap. A few examples of targetable biomarkers that we identified as emerging include ENO1, nectin-4, TROP2, PCSK9, LILRB1, CEACAM5, and the immune checkpoint molecule TIGIT.